For You
News & Perspective
Drugs & Diseases
CME & Education
Academy
Video
Decision Point

Specialty: Multispecialty
Allergy & Immunology
Anesthesiology
Business of Medicine
Cardiology
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Medicine
Gastroenterology
General Surgery
Hematology - Oncology
HIV/AIDS
Hospital Medicine
Infectious Diseases
Internal Medicine
Multispecialty
Nephrology
Neurology
Ob/Gyn & Women's Health
Oncology
Ophthalmology
Orthopedics
Pathology & Lab Medicine
Pediatrics
Plastic Surgery
Psychiatry
Public Health
Pulmonary Medicine
Radiology
Rheumatology
Transplantation
Urology
Medical Students
Nurses
Pharmacists
Residents
Today on Medscape
Edition: ENGLISH
DEUTSCH
ESPAÑOL
FRANÇAIS
PORTUGUÊS
Sign Up It's Free!
Edition: ENGLISH DEUTSCH ESPAÑOL FRANÇAIS PORTUGUÊS

No Results

    Saturday, October 16, 2021
    For You News & Perspective Drugs & Diseases CME & Education Academy Video Decision Point
    Drugs & Diseases > Oncology > Non-Small Cell Lung Cancer (NSCLC) Treatment Protocols Q&A

    What are the first-line treatment options for metastatic (stage IV) non-small cell lung cancer (NSCLC) in patients who are not candidates for targeted therapies?

    Updated: Jul 15, 2021
    • Author: Marvaretta M Stevenson, MD; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
    • Print
    Answer

    Answer

    First-line treatment options if not a candidate for targeted therapy

    First-line treatment options for patients who are not candidates for targeted therapy are listed below. Unless otherwise specified, the goal is to treat for four to six cycles.

    Chemotherapy regimens, including platinum-based doublets, for non-squamous and squamous histologies, are as follows:

    • Cisplatin 75 mg/m2 IV on day 1 plus  paclitaxel 175 mg/m2 IV on day 1 every 21 d [29, 30]  or

    • Cisplatin 100 mg/m2 IV on day 1 plus  gemcitabine 1000 mg/m2 IV on days 1, 8, and 15 every 28 d [30]  or

    • Cisplatin 60 mg/m2 IV on day 1 plus  gemcitabine 1000 mg/m2 IV on days 1 and 8 every 21 d [31, 32]  or

    • Cisplatin 75 mg/m2 IV on day 1 plus  docetaxel 75 mg/m2 IV on day 1 every 21 d [8, 30]  or

    • Carboplatin AUC 6 IV on day 1 plus  paclitaxel 175-225 mg/m2 IV on day 1 every 21 d [30, 33]  or

    • Carboplatin AUC 6 IV on day 1 plus  paclitaxel 90 mg/m2 IV on days 1, 8, and 15 every 28 d [34, 35, 36]  or

    • Paclitaxel protein bound 100 mg/m2 IV on days 1, 8, and 15 of every 21 d plus carboplatin AUC 6 IV on day 1 [37]  or

    • Carboplatin AUC 6 IV on day 1 plus  docetaxel 75 mg/m2 IV on day 1 every 21 d [19]  or

    • Carboplatin AUC 5 IV on day 1 plus  gemcitabine 1250 mg/m2 IV on days 1 and 8 every 21 d [38, 39, 40]  or

    • Cisplatin 100 mg/m2 IV on day 1 every 28 d plus  vinorelbine 25 mg/m2 IV weekly [8] or

    • Cisplatin 40 mg/m2 IV on day 1 plus  vinorelbine 25 mg/m2 IV on days 1 and 8 every 21 d [31]  or

    • Carboplatin AUC 5 IV on day 1 plus  vinorelbine 30 mg/m2 IV on days 1 and 8 every 21 d [41]

    Combination immunotherapy for first-line treatment of metastatic NSCLC with PD-L1 tumor expression ≥1% is as follows [42] :

    • Nivolumab 3 mg/kg IV q2wk,  plus
    • Ipilimumab 1 mg/kg IV q6wk
    • Continue until disease progression, unacceptable toxicity, or for up to 2 years in patients without disease progression

    First-line treatment of metastatic squamous NSCLC is as follows:

    • Paclitaxel protein bound 100 mg/m2 IV on days 1, 8, and 15 of every 21 d plus carboplatin AUC 6 IV on day 1 [37]   or
    • Pembrolizumab 200 mg IV  and  carboplatin AUC 6 mg/mL/min on day 1 of each 21 d cycle for four cycles  plus  paclitaxel 200 mg/m 2 on day 1  or  nab-paclitaxel 100 mg/m 2 on days 1, 8, and 15 of each 21 d cycle for four cycles [43] ; alternative pembrolizumab dose is 400 mg q6wk  [28] ​

    Bevacizumab-based regimens for patients who meet eligibility requirements (non-squamous histology, treated brain metastases, no history of hemoptysis) are as follows:

    • Carboplatin AUC 6 IV on day 1 plus  paclitaxel 200 mg/m2 IV on day 1 plus  bevacizumab 15 mg/kg IV on day 1 every 21 d (continue bevacizumab every 21 d after four to six cycles are completed; continue until disease progression) [44]  or

    • Cisplatin 80 mg/m2 IV on day 1 plus  gemcitabine 1250 mg/m2 IV on days 1 and 8 plus  bevacizumab 7.5-15 mg/kg IV on day 1 every 21 d (continue bevacizumab every 21 d after four to six cycles are completed); continue until disease progression or

    • Docetaxel 75 mg/m2 IV on day 1 plus  bevacizumab 15 mg/kg IV on day 1 every 21 d until disease progression or 52 wk of therapy [14] or

    • Carboplatin AUC 6 IV on day 1 plus  pemetrexed 500 mg/m2 IV on day 1 plus  bevacizumab 15 mg/kg IV on day 1 every 21 d, with pemetrexed and bevacizumab continued until disease progression (plus folate and vitamin B12 supplements, along with dexamethasone premedication for pemetrexed) [45]

    Pemetrexed plus pembrolizumab plus platinum therapy regimens for initial treatment in patients with nonsquamous NSCLC without EGFR or ALK genomic tumor aberrations are as follows: [46]

    • Pembrolizumab 200 mg plus  pemetrexed 500 mg/m2 plus  cisplatin 75 mg/m2 IV on day 1 every 21 d for four cycles (plus folate and vitamin B12 supplements along with dexamethasone premedication for pemetrexed) or

    • Pembrolizumab 200 mg plus  pemetrexed 500 mg/m2 plus carboplatin AUC 5 IV on day 1 every 21 d for four cycles (plus folate and vitamin B12 supplements along with dexamethasone premedication for pemetrexed)

    • Administer pemetrexed IV over 10 min after pembrolizumab and before platinum-based therapy

    • Alternative pembrolizumab dose is 400 mg IV q6wk

    • Following treatment with platinum-based therapy, continue pemetrexed with or without pembrolizumab until disease progression or unacceptable toxicity

    Pemetrexed plus cisplatin for initial treatment in patients with nonsquamous NSCLC:

    • Pemetrexed 500 mg/m 2 IV administered 10 minutes before cisplatin 75 mg/m2 IV on day 1 every 21 d for up to six cycles in the absence of disease progression or unacceptable toxicity

    Pembrolizumab can be used as a single-agent first-line for tumors that express PD-L1 (Tumor Proportion Score [TPS] ≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as follows: [47, 48]

    • Pembrolizumab 200 mg IV q3wk or 400 mg IV q6wk until disease progression or unacceptable toxicity, or up to 24 months in patients without disease progression

    Pembrolizumab is also indicated in combination with pemetrexed and carboplatin for first-line treatment of patients with metastatic nonsquamous NSCLC irrespective of PD-L1 expression, as follows: [46]

    • Pembrolizumab 200 mg IV plus pemetrexed 500 mg/m 2 plus carboplatin (AUC 5 mg/mL/min) IV on Day 1 of each 21-day cycle for four cycles,  then pembrolizumab 200 mg IV q3wk until disease progression or unacceptable toxicity, or up to 24 months in patients without disease progression
    • Alternatively, pembrolizumab 400 mg IV q6wk plus pemetrexed 500 mg/m2 plus carboplatin (AUC 5 mg/mL/min) IV on Day 1 of each 21-day cycle for four cycles,  then pembrolizumab 400 mg IV q6wk until disease progression or unacceptable toxicity, or up to 24 months in patients without disease progression

    Treatment recommendations for patients with contraindications to carboplatin or cisplatin are as follows: 

    • Gemcitabine 1100 mg/m2 IV on days 1 and 8 plus docetaxel 100 mg/m2 IV on day 8 every 21 d [49, 50]  or

    • Gemcitabine 1000-1200 mg/m2 IV on days 1 and 8 plus vinorelbine 25-30 mg/m2 IV on days 1 and 8 every 21 d [41, 51, 52, 53]

    Read More
    Did this answer your question?
    Additional feedback? (Optional)
    Thank you for your feedback!
    Media Gallery
    of 0
    Find Us On
    About
    About Medscape Privacy Policy Editorial Policy Cookies Terms of Use Advertising Policy Help Center
    Membership
    Become a Member About You Professional Information Newsletters & Alerts
    Apps
    Medscape CME & Education
    WebMD Network
    Medscape Live Events WebMD MedicineNet eMedicineHealth RxList WebMD Corporate
    Editions
    English Deutsch Español Français Português
    All material on this website is protected by copyright, Copyright © 1994-2021 by WebMD LLC. This website also contains material copyrighted by 3rd parties.